# Autologous Dendritic Cell Vaccine in Kidney Cancer

> **NCT05127824** · PHASE2 · RECRUITING · sponsor: **Jodi Maranchie** · enrollment: 42 (estimated)

## Conditions studied

- Carcinoma, Renal Cell

## Interventions

- **BIOLOGICAL:** Autologous alpha-DC1/TBVA vaccine
- **DRUG:** Cabozantinib

## Key facts

- **NCT ID:** NCT05127824
- **Lead sponsor:** Jodi Maranchie
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-06
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2025-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05127824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05127824, "Autologous Dendritic Cell Vaccine in Kidney Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05127824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*